Skip to main content
Top
Published in: Breast Cancer Research 2/2008

Open Access 01-04-2008 | Research article

Differentiation of angiogenic burden in human cancer xenografts using a perfusion-type optical contrast agent (SIDAG)

Authors: Alexander Wall, Thorsten Persigehl, Peter Hauff, Kai Licha, Michael Schirner, Silke Müller, Angelika von Wallbrunn, Lars Matuszewski, Walter Heindel, Christoph Bremer

Published in: Breast Cancer Research | Issue 2/2008

Login to get access

Abstract

Introduction

Use of fluorescence imaging in oncology is evolving rapidly, and nontargeted fluorochromes are currently being investigated for clinical application. Here, we investigated whether the degree of tumour angiogenesis can be assessed in vivo by planar and tomographic methods using the perfusion-type cyanine dye SIDAG (1,1'-bis- [4-sulfobutyl]indotricarbocyanine-5,5'-dicarboxylic acid diglucamide monosodium).

Method

Mice were xenografted with moderately (MCF7, DU4475) or highly vascularized (HT1080, MDA-MB435) tumours and scanned up to 24 hours after intravenous SIDAG injection using fluorescence reflectance imaging. Contrast-to-noise ratio was calculated for all tumours, and fluorochrome accumulation was quantified using fluorescence-mediated tomography. The vascular volume fraction of the xenografts, serving as a surrogate marker for angiogenesis, was measured using magnetic resonance imaging, and blood vessel profile (BVP) density and vascular endothelial growth factor expression were determined.

Results

SIDAG accumulation correlated well with angiogenic burden, with maximum contrast to noise ratio for MDA-MB435 (P < 0.0001), followed by HT1080, MCF7 and DU4475 tumours. Fluorescence-mediated tomography revealed 4.6-fold higher fluorochrome concentrations in MDA-MB435 than in DU4475 tumours (229 ± 90 nmol/l versus 49 ± 22 nmol/l; P < 0.05). The vascular volume fraction was 4.5-fold (3.58 ± 0.9% versus 0.8 ± 0.53%; P < 0.01), blood vessel profile density 5-fold (399 ± 36 BVPs/mm2 versus 78 ± 16 BVPs/mm2) and vascular endothelial growth factor expression 4-fold higher for MDA-MB435 than for DU4475 tumours.

Conclusion

Our data suggest that perfusion-type cyanine dyes allow assessment of angiogenesis in vivo using planar or tomographic imaging technology. They may thus facilitate characterization of solid tumours.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cheng X, Mao JM, Bush R, Kopans DB, Moore RH, Chorlton M: Breast cancer detection by mapping hemoglobin concentration and oxygen saturation. Appl Opt. 2003, 42: 6412-6421.CrossRefPubMed Cheng X, Mao JM, Bush R, Kopans DB, Moore RH, Chorlton M: Breast cancer detection by mapping hemoglobin concentration and oxygen saturation. Appl Opt. 2003, 42: 6412-6421.CrossRefPubMed
2.
go back to reference Taroni P, Danesini G, Torricelli A, Pifferi A, Spinelli L, Cubeddu R: Clinical trial of time-resolved scanning optical mammography at 4 wavelengths between 683 and 975 nm. J Biomed Opt. 2004, 9: 464-473.CrossRefPubMed Taroni P, Danesini G, Torricelli A, Pifferi A, Spinelli L, Cubeddu R: Clinical trial of time-resolved scanning optical mammography at 4 wavelengths between 683 and 975 nm. J Biomed Opt. 2004, 9: 464-473.CrossRefPubMed
3.
go back to reference Grosenick D, Moesta KT, Wabnitz H, Mucke J, Stroszczynski C, Macdonald R, Schlag PM, Rinneberg H: Time-domain optical mammography: initial clinical results on detection and characterization of breast tumors. Appl Opt. 2003, 42: 3170-3186.CrossRefPubMed Grosenick D, Moesta KT, Wabnitz H, Mucke J, Stroszczynski C, Macdonald R, Schlag PM, Rinneberg H: Time-domain optical mammography: initial clinical results on detection and characterization of breast tumors. Appl Opt. 2003, 42: 3170-3186.CrossRefPubMed
4.
go back to reference Ntziachristos V, Chance B: Probing physiology and molecular function using optical imaging: applications to breast cancer. Breast Cancer Res. 2001, 3: 41-46.CrossRefPubMed Ntziachristos V, Chance B: Probing physiology and molecular function using optical imaging: applications to breast cancer. Breast Cancer Res. 2001, 3: 41-46.CrossRefPubMed
5.
go back to reference Floery D, Helbich TH, Riedl CC, Jaromi S, Weber M, Leodolter S, Fuchsjaeger MH: Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience. Invest Radiol. 2005, 40: 328-335.CrossRefPubMed Floery D, Helbich TH, Riedl CC, Jaromi S, Weber M, Leodolter S, Fuchsjaeger MH: Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience. Invest Radiol. 2005, 40: 328-335.CrossRefPubMed
6.
go back to reference Bremer C, Ntziachristos V, Weissleder R: Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol. 2003, 13: 231-243.PubMed Bremer C, Ntziachristos V, Weissleder R: Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol. 2003, 13: 231-243.PubMed
7.
go back to reference Ntziachristos V, Yodh AG, Schnall M, Chance B: Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci USA. 2000, 97: 2767-2772.CrossRefPubMedPubMedCentral Ntziachristos V, Yodh AG, Schnall M, Chance B: Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci USA. 2000, 97: 2767-2772.CrossRefPubMedPubMedCentral
8.
go back to reference Riefke B, Licha K, Semmler W: Contrast media for optical mammography [in German]. Radiologe. 1997, 37: 749-755.CrossRefPubMed Riefke B, Licha K, Semmler W: Contrast media for optical mammography [in German]. Radiologe. 1997, 37: 749-755.CrossRefPubMed
9.
go back to reference Licha K, Riefke B, Ntziachristos V, Becker A, Chance B, Semmler W: Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. Photochem Photobiol. 2000, 72: 392-398.CrossRefPubMed Licha K, Riefke B, Ntziachristos V, Becker A, Chance B, Semmler W: Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. Photochem Photobiol. 2000, 72: 392-398.CrossRefPubMed
10.
go back to reference Ebert B, Sukowski U, Grosenick D, Wabnitz H, Moesta KT, Licha K, Becker A, Semmler W, Schlag PM, Rinneberg H: Near-infrared fluorescent dyes for enhanced contrast in optical mammography: phantom experiments. J Biomed Opt. 2001, 6: 34-140.CrossRef Ebert B, Sukowski U, Grosenick D, Wabnitz H, Moesta KT, Licha K, Becker A, Semmler W, Schlag PM, Rinneberg H: Near-infrared fluorescent dyes for enhanced contrast in optical mammography: phantom experiments. J Biomed Opt. 2001, 6: 34-140.CrossRef
11.
go back to reference Perlitz C, Licha K, Scholle FD, Ebert B, Bahner M, Hauff P, Moesta KT, Schirner M: Comparison of two tricarbocyanine-based dyes for fluorescence optical imaging. J Fluoresc. 2005, 15: 443-455.CrossRefPubMed Perlitz C, Licha K, Scholle FD, Ebert B, Bahner M, Hauff P, Moesta KT, Schirner M: Comparison of two tricarbocyanine-based dyes for fluorescence optical imaging. J Fluoresc. 2005, 15: 443-455.CrossRefPubMed
12.
go back to reference Boehm T, Hochmuth A, Malich A, Reichenbach JR, Fleck M, Kaiser WA: Contrast-enhanced near-infrared laser mammography with a prototype breast scanner: feasibility study with tissue phantoms and preliminary results of imaging experimental tumors. Invest Radiol. 2001, 36: 573-581.CrossRefPubMed Boehm T, Hochmuth A, Malich A, Reichenbach JR, Fleck M, Kaiser WA: Contrast-enhanced near-infrared laser mammography with a prototype breast scanner: feasibility study with tissue phantoms and preliminary results of imaging experimental tumors. Invest Radiol. 2001, 36: 573-581.CrossRefPubMed
13.
go back to reference von Wallbrunn A, Höltke C, Zühlsdorf M, Heindel W, Schäfers M, Bremer C: In vivo imaging of integrin alphavbeta3 expression using fluorescence-mediated tomography. Eur J Nucl Med Mol Imaging. 2007, 34: 745-754.CrossRefPubMed von Wallbrunn A, Höltke C, Zühlsdorf M, Heindel W, Schäfers M, Bremer C: In vivo imaging of integrin alphavbeta3 expression using fluorescence-mediated tomography. Eur J Nucl Med Mol Imaging. 2007, 34: 745-754.CrossRefPubMed
14.
go back to reference Montet X, Ntziachristos V, Grimm J, Weissleder R: Tomographic fluorescence mapping of tumor targets. Cancer Res. 2005, 65: 6330-6336.CrossRefPubMed Montet X, Ntziachristos V, Grimm J, Weissleder R: Tomographic fluorescence mapping of tumor targets. Cancer Res. 2005, 65: 6330-6336.CrossRefPubMed
15.
go back to reference Kessler T, Bieker R, Padró T, Schwöppe C, Persigehl T, Bremer C, Kreuter M, Berdel WE, Mesters RM: Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res. 2005, 11: 6317-6324.CrossRefPubMed Kessler T, Bieker R, Padró T, Schwöppe C, Persigehl T, Bremer C, Kreuter M, Berdel WE, Mesters RM: Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res. 2005, 11: 6317-6324.CrossRefPubMed
16.
go back to reference Bremer C, Mustafa M, Bogdanov A, Ntziachristos V, Petrovsky A, Weissleder R: Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology. 2003, 226: 214-220.CrossRefPubMed Bremer C, Mustafa M, Bogdanov A, Ntziachristos V, Petrovsky A, Weissleder R: Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology. 2003, 226: 214-220.CrossRefPubMed
17.
go back to reference Turetschek K, Huber S, Floyd E, Helbich T, Roberts TP, Shames DM, Tarlo KS, Wendland MF, Brasch RC: MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology. 2001, 218: 562-569.CrossRefPubMed Turetschek K, Huber S, Floyd E, Helbich T, Roberts TP, Shames DM, Tarlo KS, Wendland MF, Brasch RC: MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology. 2001, 218: 562-569.CrossRefPubMed
18.
go back to reference Gundersen HJ, Jensen EB: The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987, 147: 229-263.CrossRefPubMed Gundersen HJ, Jensen EB: The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987, 147: 229-263.CrossRefPubMed
19.
go back to reference Mori A, Arii S, Furutani M, Hanaki K, Takeda Y, Moriga T, Kondo Y, Gorrin Rivas MJ, Imamura M: Vascular endothelial growth factor-induced tumor angiogenesis and tumorigenicity in relation to metastasis in a HT1080 human fibrosarcoma cell model. Int J Cancer. 1999, 80: 738-743.CrossRefPubMed Mori A, Arii S, Furutani M, Hanaki K, Takeda Y, Moriga T, Kondo Y, Gorrin Rivas MJ, Imamura M: Vascular endothelial growth factor-induced tumor angiogenesis and tumorigenicity in relation to metastasis in a HT1080 human fibrosarcoma cell model. Int J Cancer. 1999, 80: 738-743.CrossRefPubMed
20.
go back to reference Weissleder R, Ntziachristos V: Shedding light onto live molecular targets. Nat Med. 2003, 9: 123-128.CrossRefPubMed Weissleder R, Ntziachristos V: Shedding light onto live molecular targets. Nat Med. 2003, 9: 123-128.CrossRefPubMed
21.
go back to reference Monsees B, Destouet JM, Gersell D: Light scan evaluation of nonpalpable breast lesions. Radiology. 1987, 163: 467-470.CrossRefPubMed Monsees B, Destouet JM, Gersell D: Light scan evaluation of nonpalpable breast lesions. Radiology. 1987, 163: 467-470.CrossRefPubMed
22.
go back to reference Monsees B, Destouet JM, Totty WG: Light scanning versus mammography in breast cancer detection. Radiology. 1987, 163: 463-465.CrossRefPubMed Monsees B, Destouet JM, Totty WG: Light scanning versus mammography in breast cancer detection. Radiology. 1987, 163: 463-465.CrossRefPubMed
23.
go back to reference Geslien GE, Fisher JR, DeLaney C: Transillumination in breast cancer detection: screening failures and potential. AJR Am J Roentgenol. 1985, 144: 619-622.CrossRefPubMed Geslien GE, Fisher JR, DeLaney C: Transillumination in breast cancer detection: screening failures and potential. AJR Am J Roentgenol. 1985, 144: 619-622.CrossRefPubMed
24.
go back to reference Riefke B, Licha K, Semmler W, Nolte T, Ebert B, Rinneberg HH: In vivo characterization of cyanine dyes as contrast agents for near-infrared imaging. Proc SPIE. 1996, 2927: 199-208.CrossRef Riefke B, Licha K, Semmler W, Nolte T, Ebert B, Rinneberg HH: In vivo characterization of cyanine dyes as contrast agents for near-infrared imaging. Proc SPIE. 1996, 2927: 199-208.CrossRef
25.
go back to reference Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, Brasch RC: Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatr Radiol. 1998, 28: 67-78.CrossRefPubMed Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, Brasch RC: Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatr Radiol. 1998, 28: 67-78.CrossRefPubMed
26.
go back to reference Bremer C, Tung CH, Weissleder R: In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001, 7: 743-748.CrossRefPubMed Bremer C, Tung CH, Weissleder R: In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001, 7: 743-748.CrossRefPubMed
27.
go back to reference Chen X, Conti PS, Moats RA: In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res. 2004, 64: 8009-8014.CrossRefPubMed Chen X, Conti PS, Moats RA: In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res. 2004, 64: 8009-8014.CrossRefPubMed
28.
go back to reference Bremer C, Ntziachristos V, Weitkamp B, Theilmeier G, Heindel W, Weissleder R: Optical imaging of spontaneous breast tumors using protease sensing 'smart' optical probes. Invest Radiol. 2005, 40: 321-327.CrossRefPubMed Bremer C, Ntziachristos V, Weitkamp B, Theilmeier G, Heindel W, Weissleder R: Optical imaging of spontaneous breast tumors using protease sensing 'smart' optical probes. Invest Radiol. 2005, 40: 321-327.CrossRefPubMed
29.
go back to reference Funovics MA, Weissleder R, Mahmood U: Catheter-based in vivo imaging of enzyme activity and gene expression: feasibility study in mice. Radiology. 2004, 231: 659-666.CrossRefPubMed Funovics MA, Weissleder R, Mahmood U: Catheter-based in vivo imaging of enzyme activity and gene expression: feasibility study in mice. Radiology. 2004, 231: 659-666.CrossRefPubMed
30.
go back to reference Soltesz EG, Kim S, Laurence RG, DeGrand AM, Parungo CP, Dor DM, Cohn LH, Bawendi MG, Frangioni JV, Mihaljevic T: Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann Thorac Surg. 2005, 79: 269-277.CrossRefPubMedPubMedCentral Soltesz EG, Kim S, Laurence RG, DeGrand AM, Parungo CP, Dor DM, Cohn LH, Bawendi MG, Frangioni JV, Mihaljevic T: Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann Thorac Surg. 2005, 79: 269-277.CrossRefPubMedPubMedCentral
31.
go back to reference Grand DJ: Case of the month. Islet cell tumor of the pancreas. Crit Rev Comput Tomogr. 2003, 44: 21-26.CrossRefPubMed Grand DJ: Case of the month. Islet cell tumor of the pancreas. Crit Rev Comput Tomogr. 2003, 44: 21-26.CrossRefPubMed
Metadata
Title
Differentiation of angiogenic burden in human cancer xenografts using a perfusion-type optical contrast agent (SIDAG)
Authors
Alexander Wall
Thorsten Persigehl
Peter Hauff
Kai Licha
Michael Schirner
Silke Müller
Angelika von Wallbrunn
Lars Matuszewski
Walter Heindel
Christoph Bremer
Publication date
01-04-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1875

Other articles of this Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine